Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune disorder that disrupts communication between nerves and muscles, leading to progressive weakness. While often linked to underlying cancer, particularly small-cell lung cancer, it can also occur independently. Early diagnosis and treatment are crucial for managing symptoms and improving quality of life.
What Happens in LEMS?
The core problem in LEMS is a breakdown at the neuromuscular junction – the point where nerve signals tell muscles to contract. The immune system mistakenly attacks voltage-gated calcium channels, which are essential for releasing acetylcholine, the chemical messenger muscles need to move. Less acetylcholine means weaker muscle contractions.
Key symptoms include:
- Gradual muscle weakness, starting in the hips and thighs
- Decreased or absent reflexes
- Autonomic dysfunction (dry mouth, constipation, dizziness)
- Oculobulbar symptoms (drooping eyelids, double vision, swallowing difficulties)
A unique feature is post-exercise facilitation, where strength temporarily improves after brief activity.
Causes and Diagnosis
Around 60% of LEMS cases are paraneoplastic, meaning they develop alongside cancer. The remaining cases are autoimmune, with no detectable tumor. Because symptoms overlap with other conditions, diagnosis involves:
- Blood tests: To detect antibodies against calcium channels
- Electrodiagnostic testing (EMG): To confirm nerve-muscle dysfunction
- Cancer screening: Including CT or PET scans, given the high cancer association
Early cancer detection is vital, as treating the tumor can also improve neurological symptoms.
Treatment Strategies
LEMS management focuses on three key areas: treating any underlying cancer, improving nerve-muscle communication, and suppressing the immune attack.
- Cancer treatment: If present, chemotherapy, radiation, or surgery are used.
- Medications:
- Amifampridine (Firdapse) is the first-line treatment, increasing acetylcholine release.
- Pyridostigmine (Mestinon) may provide additional symptom relief.
- Immune-modulating therapies: Corticosteroids, immunosuppressants (azathioprine, cyclosporine), or intravenous immunoglobulin (IVIG) can reduce autoimmune activity.
Severe cases may require plasma exchange or high-dose immunoglobulin therapy for short-term relief.
Long-Term Outlook
Prognosis varies. People with non-cancer LEMS often have a normal lifespan with ongoing management. Cancer-related LEMS outcomes depend on tumor stage and treatment success. Lifestyle adjustments, such as avoiding smoking and maintaining a healthy diet, can support overall health.
Potential complications include: falls, infections (especially pneumonia), and progressive disability if untreated.
Early diagnosis, aggressive cancer treatment when applicable, and tailored medical management are key to improving function and quality of life in individuals with Lambert-Eaton myasthenic syndrome.
